Tagged with OP

Pharma The traditional model of healthcare has generally been limited to treatment in health facilities. But, when it comes to effectively treating more private and deeply personal health conditions, especially in South Africa, companies such as Coloplast have untaken substantial efforts to partner hand-in-hand with patients through support programs that focus…

Pharma Dr. Osvaldo Ponchiroli, CEO of OP Pharma, discusses the expertise his company can offer to help navigate Italy’s regulatory environment, the outlook for medium-sized generics companies in Italy and OP’s plans for international expansion. Dr. Ponchiroli, you founded OP pharma in 1996 as a data management and generics company mainly…

Pharma Shire France’s General Manager, Andrew Obenshain, speaks optimistically about the leading market conditions in France, the corporate culture of a multinational company in a niche market, and building a rapport with government and patients. As an American working in France, what are your key observations about the differences and similarities…

Pharma Alexander Zehnder discusses Sanofi’s sizable contribution to the Italian economy, manufacturing in Italy, and the country’s labyrinthine drug approval processes. What have been your main areas of focus and priorities since your appointment as head of Sanofi’s Italy and Malta operations in October 2014? Sanofi is in the midst of a transition from…

Pharma The dynamic Director of ESCP Europe’s Master in Biopharmaceutical Management talks about being the reference higher education institution for programs catering to the biopharma sector, plans for more international visibility, and some notable alumni of the university’s executive level curriculum. ESCP Europe appears to have a special connection to the…

Pharma Jan Pelle Mariëtte van der Velden-Roesink Jan Pelle (JP) and Mariëtte van der Velden-Roesink (MDR) of the Brabant Development Agency (BOM) explain how they strive to offer “red-carpet treatment” to foreign investors and local companies to ultimately strengthen a life sciences eco-system based on open innovation and interdisciplinarity. As an…

Pharma Boston Scientific is raising the bar for medical devices and services in the field of cardiology and other pathologies, including Rhythm Management, Endoscopy, Urology Pelvic Health, and Neurostimulation. European President Eric Thépaut shares why Europe has been dubbed the company’s “growth lab”. Boston Scientific has positioned itself to pave the…

Pharma The Director-General of the Gustave Roussy Institute, a top cancer institute in Europe, talks about the revamping of their clinical research infrastructure to adapt to the rising new field of translational research and his ambitious plans for the next five years, in particular, his vision for Cancer Core Europe, positioned…

Pharma Yann Quentric has assumed new responsibilities as president of Iris Pharma; leading the first CRO to specialize exclusively in ophthalmology. From the company’s humble beginnings in southern France to its current international reach, Mr. Quentric shares his vision on the next chapter for the company. Can you start by introducing Iris Pharma…

Pharma Manlio Florenzano discusses Sandoz’s engagement in Italy and the role of generics firms in contributing to a more affordable and sustainable Italian healthcare system. Can you please start by introducing Sandoz’s historic engagement with the Italian market? Sandoz began marketing in Italy back in 2000. My own background, meanwhile, was…

Pharma Novartis Italy’s Georg Schroeckenfuchs discusses the impact of the company’s global restructuring on the Italian affiliate, the significance of local manufacturing, new products, and how the Novartis has managed to become a market leader in Italy. A lot has been happening with Novartis globally lately: with big changes to the…

Pharma Pharmaceuticals Eugenio Aringhieri discusses Dompé’s shift in strategy towards opthalmology, instilling an innovation mindset, and broadening the company’s international horizons. Since we last interviewed you in 2009 a lot has happened: you were made European CEO in 2015 for having steered Dompé through considerable renewal and restructuring, the company also embarked…